Personalized Treatment of Advanced Gastric Cancer Guided by the MiniPDX Model

Table 3

Treatment after enrollment, clinical response, and side effects.

Patient number	Treatment regimen after drug selection	Clinical outcome	Side effects
#1	Sintilimab: 200 mg d1, nab-paclitaxel: 180 mg d1, 8, q21d2 cycles	PR	Leukopenia (grade II)
			Thrombocytopenia (grade II)
			Alopecia (grade I)
#2	Docetaxel: 60 mg d1, 8, S-1: 60 mg PO bid d1-14, q21d2 cycles	PR	Alopecia (grade I)
			Leukopenia (grade I)
#3	Apatinib: 250 mg PO qd2 cycles	PD	Nausea (grade II)
			Anemia (grade II)
#4	Camrelizumab: 200 mg d1 q14 d, docetaxel: 60 mg d1, 8, apatinib: 250 mg PO qd1 cycle, q21d	PD	Nausea (grade II)
			Vomiting (grade II)
			Alopecia (grade I)

Notes: All drugs were used intravenously if not mentioned otherwise. Side effects were graded according to the CTCAEv5.0 standards.